Atlas Trials

Study Exploring the Effect of Crizanlizumab on Kidney Function in Patients With Chronic Kidney Disease Caused by Sickle Cell Disease

Clinical trial NCT04053764 · COMPLETED

Trial details

NCT number
NCT04053764
Sponsor
Novartis Pharmaceuticals
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Sickle Cell Disease (SCD)
Start date
2019-12-10
Primary completion
2023-03-20
Enrollment
58

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.